Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.85    -0.22 (-2.50%)
Bid:
8.50
Ask:
9.20
Spread: 0.70 (8.235%)
Market Cap: £56.22m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Progress with global OEM contract

22 Sep 2014 07:00

RNS Number : 1959S
Kromek Group PLC
22 September 2014
 



22 September 2014

 

Kromek Group plc

("Kromek" or the "Company")

 

Kromek Progresses to Second Year of Development Contract with Global OEM in CT Medical Imaging Markets

 

Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that a top four Original Equipment Manufacturer ("OEM") in the Computed Tomography ("CT") market has confirmed its decision to progress to the second year of a previously announced programme with the Company. Kromek has received a $1m exclusivity payment for the second year.

 

This payment is part of a programme that comes under Kromek's mutually exclusive development contract, worth up to $5.3m, with the OEM for developing and supplying Cadmium Zinc Telluride ("CZT") based multispectral (colour) detectors for producing high resolution colour X-Ray images by CT scanners. The decision to continue the programme for the second year was based on sustained progress towards meeting the aims of the development programme.

 

Arnab Basu, CEO of Kromek, said: "We are delighted to be progressing this project to advance colour CT imaging, which can lead to major healthcare benefits for diagnosis and treatment of cancers, cardiovascular diseases and other pathologies. With the success of our collaboration, our relationship with this key OEM partner continues to develop and grow stronger. This latest step is a clear endorsement of our technology and our long-term strategy to position Kromek's subcomponents at the heart of major global OEMs' medical imaging systems to improve diagnostic capabilities, resulting in better clinical outcomes."

 

This contract does not change the Company's expectations for the year ended 30 April 2015. However, it provides further evidence of the progress towards meeting market expectations.

 

Arnab Basu, CEO, and Derek Bulmer, CFO, will be hosting a webinar today at 12pm where they will give a presentation on their results for the year ended 30 April 2014. No additional disclosure will be made about financials or current trading further to the Company's announcement released on 28 August 2014. Analysts and investors wishing to join can register at:

https://attendee.gotowebinar.com/register/5530034774550287105

Enquiries

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

01740 626 060

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley - Corporate Finance

Charles Leigh-Pemberton - Broking

0207 886 2500

Luther Pendragon

Harry Chathli, Claire Norbury, Alexis Gore, Ivana Petkova

0207 618 9100

 

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 250 pieces of IP.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAENFADDLEAF
Date   Source Headline
8th Dec 20207:00 amRNSContract extensions for D3S products
3rd Dec 20207:00 amRNSKromek launches the D5 RIID radiation detector
2nd Nov 20207:00 amRNSKromek wins new sector-leading global OEM customer
2nd Nov 20207:00 amRNSResult of AGM
29th Oct 20207:00 amRNSDirectorate Change
14th Oct 20207:00 amRNSKromek CZT technology to improve cancer surgery
9th Oct 20204:41 pmRNSSecond Price Monitoring Extn
9th Oct 20204:36 pmRNSPrice Monitoring Extension
8th Oct 20205:28 pmRNSHolding(s) in Company
8th Oct 20204:44 pmRNSNotice of AGM and Publication of Annual Report
8th Oct 202012:58 pmRNSDirector Share Purchase
8th Oct 20207:00 amRNSAppointment of Non-executive Director
7th Oct 202011:13 amRNSDirector Share Purchase
7th Oct 202011:00 amRNSPrice Monitoring Extension
7th Oct 20207:00 amRNSFinal Results
28th Sep 20203:00 pmRNSHolding(s) in Company
17th Sep 20201:53 pmRNSHolding(s) in Company
27th May 20207:00 amRNSKromek awarded new DARPA bio-surveillance contract
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20209:05 amRNSSecond Price Monitoring Extn
1st May 20209:00 amRNSPrice Monitoring Extension
1st May 20207:00 amRNSFull Year Trading Update and Response to COVID-19
27th Apr 202010:57 amRNSHolding(s) in Company
21st Apr 20207:00 amRNSKromek receives Queen’s Award
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSKromek to produce ventilators to fight COVID-19
20th Mar 202010:52 amRNSHolding(s) in Company
18th Feb 20204:15 pmRNSHolding(s) in Company
27th Jan 202012:42 pmRNSSite visit by International Trade Secretary
9th Jan 20204:55 pmRNSHolding(s) in Company
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20197:00 amRNSDirector Share Purchase
12th Dec 20197:00 amRNSDirector Share Purchases
11th Dec 20197:00 amRNSInterim Results
5th Dec 20197:00 amRNSNotice of Results
4th Dec 20195:25 pmRNSHolding(s) in Company
26th Sep 20191:14 pmRNSResult of AGM
24th Sep 20197:00 amRNSKromek awarded two contracts for D3S products
30th Aug 20191:50 pmRNSNotice of AGM and Publication of Annual Report
1st Jul 20197:00 amRNSNew contracts for D3S in UK, US and Europe
27th Jun 20197:00 amRNSFinal Results
7th May 20197:00 amRNSTrading Update
1st May 20197:00 amRNSSecurity screening contract order expansion
29th Mar 20194:51 pmRNSChange of Adviser
18th Mar 20195:50 pmRNSDirector Dealings Correction
28th Feb 20191:00 pmRNSHolding(s) in Company
28th Feb 20191:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.